{"entity":{"id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HSK39775 Monotherapy in advanced solid tumours, run by Xizang Haisco Pharmaceutical Co., Ltd, now recruiting.","summary":"A Study for HSK39775 in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06314373 by Xizang Haisco Pharmaceutical Co., Ltd, with 243 participants planned, started 2024-03-07 and due to reach its primary completion in 2028-02-01. Interventions recorded: HSK39775 Monotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06314373","url":"https://clinicaltrials.gov/study/NCT06314373"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06314373","phase":"1/2","setting":"A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies","sponsor":"Xizang Haisco Pharmaceutical Co., Ltd","enrolled":243,"outcomes":[]},"route":"/trials/nct06314373/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}